An evaluation of anti-TNF-alpha-therapy in patients with ankylosing spondylitis: imbalanced activation of NF kappa B subunits in lymphocytes and modulation of serum cortisol concentration

[1]  A. Agrawal,et al.  Regulation of Basal and Induced Expression of C-Reactive Protein through an Overlapping Element for OCT-1 and NF-κB on the Proximal Promoter , 2005, The Journal of Immunology.

[2]  Christos G. Papadopoulos,et al.  Infliximab treatment in ankylosing spondylitis: an observational study , 2004, Annals of the rheumatic diseases.

[3]  M. Schmitz,et al.  The NF-kappaB pathway as a potential target for autoimmune disease therapy. , 2004, Current pharmaceutical design.

[4]  U. Zettl,et al.  Transcription factors in autoimmune diseases. , 2004, Current pharmaceutical design.

[5]  M. Stone,et al.  Recent advances in the treatment of the spondyloarthropathies , 2004, Current opinion in rheumatology.

[6]  K. Scalapino,et al.  The treatment of ankylosing spondylitis , 2003, Clinical and Experimental Medicine.

[7]  R. Renkawitz,et al.  Expression analysis of the glucocorticoid receptor and the nuclear factor-kB subunit p50 in lymphocytes from patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.

[8]  R. Renkawitz,et al.  Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis. , 2002, Cytokines, cellular & molecular therapy.

[9]  A. Boonen,et al.  Ankylosing spondylitis: an overview , 2002, Annals of the rheumatic diseases.

[10]  M. Brown,et al.  Genetic aspects of susceptibility, severity, and clinical expression in ankylosing spondylitis , 2002, Current opinion in rheumatology.

[11]  C. Brinckerhoff,et al.  Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors , 2001, Arthritis Research & Therapy.

[12]  J. Braun,et al.  Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. , 2000, Arthritis and rheumatism.

[13]  G. Ghosh,et al.  Regulation of DNA binding by Rel/NF-κB transcription factors: structural views , 1999, Oncogene.

[14]  H. Pahl.  Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.

[15]  C. Scheidereit,et al.  NF‐κB p105 is a target of IκB kinases and controls signal induction of Bcl‐3–p50 complexes , 1999 .

[16]  A. Baldwin,et al.  Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids , 1995, Science.

[17]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[18]  J. Marx.  How the Glucocorticoids Suppress Immunity , 1995, Science.

[19]  J. Cidlowski,et al.  Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors , 1995, Molecular and cellular biology.

[20]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[21]  A. Ray,et al.  Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Dougados,et al.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. , 1991, Arthritis and rheumatism.

[23]  M. Palanki,et al.  Inhibitors of AP-1 and NF-kappa B mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity. , 2002, Current medicinal chemistry.

[24]  J. Cidlowski,et al.  Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. , 1998, Molecular endocrinology.

[25]  P. Baeuerle,et al.  Function and activation of NF-kappa B in the immune system. , 1994, Annual review of immunology.

[26]  L. Aarden,et al.  Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. , 1988, Scandinavian journal of rheumatology.